Overview of current evidence on the impact of the initial high dose of the direct factor xa inhibitor rivaroxaban on thrombus resolution in the treatment of venous thromboembolism

International Heart Journal

Volumn 58, Issue 1, 2017, Pages 6-15

  Bauersachs, Rupert ^a,b   Koitabashi, Norimichi ^c  

^a KLINIKUM DARMSTADT   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Deep vein thrombosis; Intensive dosing; Pulmonary embolism; Residual venous thrombus; Thrombus burden

Indexed keywords

ANTIVITAMIN K; BISOPROLOL; D DIMER; DABIGATRAN; ENOXAPARIN; HEPARIN; PANTOPRAZOLE; RISEDRONIC ACID; RIVAROXABAN; TROPONIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOT LYSIS; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; FECES ANALYSIS; FEMALE; GASTRECTOMY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEG SWELLING; LIMB SWELLING; LUNG EMBOLISM; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THORAX RADIOGRAPHY; THROMBOPHILIA; VERY ELDERLY; YOUNG ADULT; DIAGNOSTIC IMAGING; ECHOGRAPHY; RECURRENT DISEASE; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; RECURRENCE; RIVAROXABAN; ULTRASONOGRAPHY; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 85011843782     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.16-617     Document Type: Review

References (55)

1. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009; 28: 401-9.
2. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139: 19-25.
3. Limone BL, Hernandez AV, Michalak D, Bookhart BK, Coleman CI. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. Thromb Res 2013; 132: 420-6.
4. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205.
5. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293: 2352-61.
6. Ruppert A, Lees M, Steinle T. Clinical burden of venous thromboembolism. Curr Med Res Opin 2010; 26: 2465-73. (Review)
7. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
8. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-8.
9. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006; 21: 23-9. (Review)
10. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38: S495-501.
11. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1: 1309-12.
12. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-9.
13. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14.
14. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
15. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
16. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
17. van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-104.
18. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 515-8.
19. van Dongen CJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005; 3: 939-42.
20. Chitsike RS, Rodger MA, Kovacs MJ, et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemost 2012; 10: 2039-44.
21. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-9.
22. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
23. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
24. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-15.
25. McRae SJ, Ginsberg JS. Initial treatment of venous thromboembolism. Circulation 2004; 110: I3-9. (Review)
26. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: I22-30. (Review)
27. Tan M, Mos IC, Klok FA, Huisman MV. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. Br J Haematol 2011; 153: 168-78. (Review)
28. Hull RD, Marder VJ, Mah AF, Biel RK, Brant RF. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med 2005; 118: 456-64. (Review)
29. Gómez-Outes A, Lecumberri R, Lafuente-Guijosa A, Martínez-González J, Carrasco P, Rocha E. Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis. J Thromb Haemost 2004; 2: 1581-7.
30. Prandoni P, Lensing AW, Prins MH, et al. The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. Semin Thromb Hemost 2015; 41: 133-40.
31. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 626-31.
32. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379: 31-8.
33. Blättler W, Heller G, Largiadèr J, Savolainen H, Gloor B, Schmidli J. Combined regional thrombolysis and surgical thrombectomy for treatment of iliofemoral vein thrombosis. J Vasc Surg 2004; 40: 620-5.
34. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-94S.
35. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149: 315-52.
36. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-69.
37. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180-7.
38. Buller HR, Lensing AWA, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 2242-7.
39. Dobesh PP, Fanikos J. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs 2014; 74: 2015-32.(Review)
40. Yamada N, Hirayama A, Maeda H, et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thromb J 2015; 13: 2.
41. van Es J, Douma RA, Kamphuisen PW, et al. Clot resolution after 3 weeks of anticoagulant treatment of pulmonary embolism: comparison of computed tomography and perfusion scintigraphy. J Thromb Haemost 2013; 11: 679-85.
42. Kuznetsov MR, Sapelkin SV, Boldin BV, Leont’ev SG, Neskhodimov LA. Recanalization of lower-limb deep veins as an index of efficacy of treatment for acute venous thrombosis. Angiol Sosud Khir 2016; 22: 82-8.(Russian)
43. Piazza G, Mani V, Goldhaber SZ, et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. Vasc Med 2016; 21: 361-8.
44. Fujino T, Yamazaki Y, Yamazaki A, et al. Efficacy of dabigatran for dissolving deep vein thromboses in outpatients with a deteriorated general condition. Int Heart J 2015; 56: 395-9.
45. Koitabashi N, Niwamae N, Taguchi T, Ohyama Y, Takama N, Kurabayashi M. Remarkable regression of massive deep vein thrombosis in response to intensive oral rivaroxaban treatment. Thromb J 2015; 13: 13.
46. Schiavoni M, Coluccia A. Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report. J Med Case Rep 2016; 10: 276.
47. Shimizu K, Sasaki T, Tomaru T, Noike H. Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report. Thromb J 2016; 14: 15.
48. Takeuchi H. Floating thrombus in the left upper pulmonary vein dissolved by dabigatran. BMJ Case Rep 2013; 2013.
49. Takeuchi H. Chest pain caused by pulmonary vein thrombi could be curable by dabigatran. BMJ Case Rep 2014; 2014.
50. Jiménez D, Aujesky D, Moores L, et al. Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170: 1383-9.
51. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041-6.
52. Fermann GJ, Erkens PM, Prins MH, Wells PS, Pap ÁF, Lensing AWA. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study. Acad Emerg Med 2015; 22: 299-307.
53. Bauersachs RM, Lensing AWA, Prins MH, et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J 2014; 12: 25.
54. van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014; 30: 829-37.
55. Becattini C, Agnelli G, Vedovati MC, et al. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J 2011; 32: 1657-63.